IL33 and cardiac hypertrophy: Angiotesin II or phenylephrine favour cardiac hypertrophy by inducing NF-kB action: IL-33, by interacting with ST2L, is able to attenuate NF-kB promoter activity and the phosphorylation of IKK [17].